

## Special Issue

# Anti-infectious Drugs in Ophthalmology

### Message from the Guest Editor

The treatment of ocular infections is essential to prevent blindness and to increase the quality of life for patients worldwide. In ophthalmology, anti-microbial agents are unique in terms of their drug formulation, dosage forms, methods of administration, pharmacokinetics and pharmacodynamics, as well as their coverage for microorganism spectra of eye infections. Summarizing and updating the knowledge on antimicrobial agents and their use in diseases with specific clinical characteristics could play a potentially powerful role on the clinical and basic development of ocular infectious disease. This special issue is dedicated to integrating our current understanding of new developments in the field of ocular anti-infectious agents, including human and veterinary applications of antimicrobial agents, epidemiological data, clinical trials, novel agents/devices and therapeutics, antimicrobial susceptibility testing methods. Manuscripts concerning all basic and clinical research on antimicrobials, antibacterials, antiviral, antifungal, and antiparasitic agents in ophthalmology are welcome.

### Guest Editor

Prof. Dr. Kaili Wu

Zhongshan Ophthalmic Center, State Key Laboratory of Ophthalmology, Sun Yat-sen University, Guangzhou 510060, China

### Deadline for manuscript submissions

closed (15 October 2022)



## Antibiotics

an Open Access Journal  
by MDPI

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/78777](https://mdpi.com/si/78777)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)